ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1565

Dissection of Ocular and Peripheral Blood Immune Phenotypes Suggests Preferential Transmigration of CD16+ Monocytes to Effector Sites in Behçet’s Disease

Yesim Ozguler1, Ziyan Lin2, Ann Cavers3, gulen Hatemi4, Olivier Manches5 and Johannes Nowatzky3, 1Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, New York, NY, 2NYU Grossman School of Medicine, NYU Langone Applied Informatics Laboratories, New York, NY, 3NYU Grossman School of Medicine, New York, NY, 4Istanbul University-Cerrahpaşa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 5Recherche et Développement, Immunobiology and Immunotherapy in Chronic Diseases, Institute for Advanced Biosciences, Inserm U 1209, CNRS UMR 5309, Université Grenoble Alpes Etablissement Français du Sang Auvergne-Rhône-Alpes, Grenoble, France

Meeting: ACR Convergence 2022

Keywords: Behçet's Syndrome, Eye Disorders, immunology, innate immunity, Monocytes/macrophages

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Vasculitis – Non-ANCA-Associated and Related Disorders Poster II

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Cellular immunity of Behçet’s Disease (BD) remains poorly understood. Previous work has provided clues pointing to most innate and adaptive immune cell types in BD, but strong signals from non-immunogenetic studies are rare and often inconclusive. Here we aimed to identify highly BD/ healthy donor (HD) discriminant immune cells in semi-biased and targeted approaches and determine their significance at a BD-relevant effector site: the eye.

Methods: We utilized multi-parametric flow cytometry to dissect cellular phenotypes in peripheral blood mononuclear cells (PBMC) of untreated BD patients (n=27) and HD (n=22) consisting predominantly of active ocular and major vascular BD subjects. Data were subjected to supervised machine learning (CITRUS), and results were verified with targeted gating. We also assessed anterior chamber (AC) fluid cells and autologous PBMC from BD uveitis patients with single-cell RNA-sequencing.

Results: CITRUS identified CD16+, CD14low, CD4low, CD3-, CD19- cells as the only BD/HD discriminant cellular expression pattern at an FDR of < 0.05. Targeted gating confirmed highly significant differences with large effect sizes in PBMC of BD vs. HD for “non-classical” (CD14lowCD16hi, p< 0.0001) and “intermediate” (CD14+CD16+, p=0.0006) monocytes at decreased frequencies for BD in peripheral blood. CD16+ dendritic cells (DC) were also significantly decreased in BD PBMC vs. HD. The effect sizes and significance levels in the CD16+ DC comparisons were inversely proportional to the level of HLA-DR expression. “Classical” (CD14++CD16-) monocytes were significantly more frequent in BD PBMC than in HD (p=0.021), but with smaller effect sizes. CD14+ cells showed a strong presence in the AC of the eye during BD uveitis and co-expressed CD16 far more frequently than CD14+ cells in autologous peripheral blood.

Conclusion: Significant differences in frequencies of CD16+ monocyte and DC subsets with large effect sizes in the peripheral blood of untreated active BD patients vs. HD point to their importance for the patho-immunobiology of BD. The high abundance of CD14+ cells with CD16 co-expression in the AC of the eye during uveitis, contrasted with their low relative frequencies in autologous peripheral blood, strongly suggests their transmigration into the eye during BD uveitis rather than a stochastic process.


Disclosures: Y. Ozguler, UCB, Novartis, Pfizer; Z. Lin, None; A. Cavers, None; g. Hatemi, Celgene, UCB, Novartis, AbbVie/Abbott; O. Manches, None; J. Nowatzky, None.

To cite this abstract in AMA style:

Ozguler Y, Lin Z, Cavers A, Hatemi g, Manches O, Nowatzky J. Dissection of Ocular and Peripheral Blood Immune Phenotypes Suggests Preferential Transmigration of CD16+ Monocytes to Effector Sites in Behçet’s Disease [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/dissection-of-ocular-and-peripheral-blood-immune-phenotypes-suggests-preferential-transmigration-of-cd16-monocytes-to-effector-sites-in-behcets-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/dissection-of-ocular-and-peripheral-blood-immune-phenotypes-suggests-preferential-transmigration-of-cd16-monocytes-to-effector-sites-in-behcets-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology